RESEARCH
ORIGINALS
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, de Lope CR, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M

J Hepatology 2019;10.1016/j.jhep.2019.01.005
Pubmed abstract
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M

Aliment Pharmacol Ther 2019;49:482-491
Pubmed abstract
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G Lancet 2017;
Pubmed abstract
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib Reig M, Torres F, Rodriguez-Lope C, Forner A, LLarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Journal of Hepatology 2014;
Pubmed abstract
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J Hepatology 2013;
Pubmed abstract
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis J.Bruix, JM.Barrera, X.Calvet, G.Ercilla, J.Costa, JM.Sanchez Tapias, M.Ventura, M. Vall, M.Bruguera, C.Bru, R.Castillo, J.Rodés. Lancet 1989;:1004-1006.
Pubmed abstract
Natural history of hepatocellular carcinoma in Spain. A five year experience in 249 cases. X.Calvet, J.Bruix, C.Bru, P.Ginès, R.Vilana, M.Sole, MC.Ayuso, M.Bruguera, J.Rodés. J Hepatol 1990;10:311-317.
Pubmed abstract
Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. R.Vilana, J. Bruix, C.Bru, C.Ayuso, M. Sole, J. Rodés. Hepatology 1992;16:353-357.
Pubmed abstract
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. A.Castells, J. Bruix, C. Bru,  J. Fuster, R.Vilana, M. Navasa, C. Ayuso, L. Boix, J. Visa, J. Rodés. Hepatology 1993;18:1121-1126.
Pubmed abstract
Treatment of hepatocellular carcinoma with tamoxifen. A Double-blind placebo controlled trial in 120 patients. A.Castells, J.Bruix, C. Brú, C.Ayuso, M. Roca, L. Boix, R. Vilana, J. Rodés. Gastroenterology 1995;109:917-922.
Pubmed abstract
Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. J. Bruix, A.Castells, J. Bosch, F.Feu, J. Fuster, J.C. Garcia Pagán, J. Visa, C. Brú, J. Rodés. Gastroenterology 1996;111:1018-1022.
Pubmed abstract
Liver transplantation for treatment of small hepatocellular carcinoma: the tumor-node- metastasis classification does not have prognostic power. JM. Llovet, J. Bruix, J. Fuster, A. Castells, JC. Garcia-Valdecasas, L.Grande, A. França, C. Brú, M.Navasa, MC. Ayuso, M. Solé, MI. Real, R. Vilana, A. Rimola, J. Visa, J. Rodés. Hepatology 1998;27:1572-1577.
Pubmed abstract
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomised, controled trial in a single institution. J. Bruix, JM. Llovet, A.Castells, X. Montanyá, C. Brú, MC. Ayuso, R. Vilana, J.Rodés. Hepatology 1998;29:173-183.
Pubmed abstract
Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus trasplantation. JM. Llovet, J. Fuster, J. Bruix. Hepatology 1999;30:1434-1440.
Pubmed abstract
Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials. JM. Llovet, J.Bustamante, A.Castells, R.Vilana, MC.Ayuso, M.Sala, C.Brú, J.Rodés, J.Bruix. Hepatology 1999;29:62-67.
Pubmed abstract
Living Donor Liver Transplantation for early Hepatocellular Carcinoma: A Life Expectancy and Cost-Effectiveness Perspective. F. Sarasin, P. Majno, JM. Llovet, J. Bruix, G. Mentha, A. Hadengue. Hepatology 2001;33:1073-1079
Pubmed abstract
Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma.: a randomised controlled trial. JM.Llovet,  MI.Real, X.  Montaña, R.  Planas, S. Coll, J.  Aponte, C. Ayuso, M. Sala,  J. Muchart, R. Solà, J. Rodés, J. Bruix for the Barcelona-Clínic-Liver Cancer Group. Lancet 2002;359:1734-1739.
Pubmed abstract
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. JM. Llovet and J. Bruix for the Barcelona-Clinic Liver Cancer Group. Hepatology 2003;37:429-442.
Pubmed abstract
MRI angiography is superior to triphasic helical CT for detection of small HCC prior liver transplantation. Comparison with pathologic correlation. M. Burrel, JM. Llovet, C. Ayuso, M. Sala, C. Iglesias, M. Solé, T. Caralt, JR. Ayuso, C. Brú, J. Bruix. Hepatology 2003;38:1034-1042.
Pubmed abstract
Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of BCLC-9 cell line. C. Armengol,  G. Tarafa, L. Boix, M. Solé, R. Queralt, D. Costa, O. Bachs, J. Bruix, G. Capella. Cancer Res. 2003;10:2150-2157.
Pubmed abstract
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. M. Sala, JM. Llovet, R. Vilana, L. Bianchi, M Solé, C. Ayuso, C. Brú and J. Bruix for the Barcelona Clínic Liver Cancer Group. Hepatology 2004;40:1352-1360.
Pubmed abstract
High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. M Sala, J Fuster, JM Llovet, M Navasa, M Sole, M Varela, F Pons, A Rimola, JC García-Valdecasas, C Bru, J Bruix; Barcelona Clinic Liver Cancer (BCLC) Group. Liver Transpl. 2004;10:1294-1300.
Pubmed abstract
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. JM Llovet, Y Chen, E Wurmbach, S Roayaie, MI Fiel, M Schwartz, SN Thung, G Khitrov, W Zhang, A Villanueva, C Battiston, V Mazzaferro, J Bruix, S Waxman, SL Friedman. Gastroenterology 2006;131:1758-1767
Pubmed abstract
Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. M Varela, MI Real, M Burrel, A forner, M Sala, M Brunet, C Ayuso, L Castells, X Montaña, JM Llovet, J Bruix. J Hepatol. J Hepatol. 2007;46:474-481
Pubmed abstract
Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnosis criteria for hepatocellular carcinoma. A Forner, R Vilana, C Ayuso, L Bianchi, M Solé, JR Ayuso, L Boix, M Sala, M Varela, JM Llovet, C Brú, J Bruix. Hepatology 2008;47:97-104.
Pubmed abstract
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. DY Chiang, A Villanueva, Y Hoshida, J Peix, P Newell, B Minguez, AC LeBlanc, DJ Donovan, SN Thung, M Solé, V Tovar, C Alsinet, AH Ramos, J Barretina, S Roayaie, M Schwartz, S Waxman, J Bruix, V Mazzaferro, AH Ligon, V Najfeld, SL Friedman, WR Sellers, M Meyerson, JM Llovet. Cancer Res. 2008;68:6779-6788.
Pubmed abstract
Sorafenib in advanced hepatocellular carcinoma. JM Llovet, S Ricci, V Mazzaferro, P Hilgard, E Gane, JF Blanc, AC de Oliveira,  A Santoro, JL Raoul, A Forner, M Schwartz, C Porta, S Zeuzem, L Bolondi, TF Greten, PR Galle, JF Seitz, I Borbath, D Häussinger, T Giannaris, M Shan, M Moscovici, D Voliotis, J Bruix; SHARP Investigators Study Group. N Engl J Med. 2008;359:378-390
Pubmed abstract
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. Y Hoshida, A Villanueva, M Kobayashi, J Peix, DY Chiang, A Camargo, S Gupta, J Moore, MJ Wrobel, J Lerner, M Reich, J, JA Chan, JN Glickman, K Ikeda, M Hashimoto, G Watanabe, MG Daidone, S Roayaie, M Schwartz, S Thung, HB Salvesen, S Gabriel, V Mazzaferro, J Bruix, SL Friedman, H Kumada, JM Llovet, TR Golub. N. England J Med 2008;359:1995-2004
Pubmed abstract
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. V. Mazzaferro, JM Llovet, R Miceli, S Bhoori, M Schiavo, L Mariani, T Camerini, S Roayaie, ME Schwartz, GL Grazi, R Adam, P Neuhaus, M Salizzoni, J Bruix, A Forner, L De Carlis, U Cillo, AK Burroughs, R Troisi, M Rossi, GE Gerunda, J Lerut, J Belghiti, I Boin, J Gugenheim, F Rochling, B Van Hoek, P Majno; Metroticket Investigator Study Group. Lancet Oncol. 2009;10:35-43.
Pubmed abstract
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?. A Forner, C Ayuso, M Varela, J Rimola, AJ Hessheimer, CR de Lope, M Reig, L Bianchi, JM Llovet, J Bruix. Cancer 2009;115:616-623.
Pubmed abstract
Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. J Rimola, A Forner, M Reig, R Vilana, CR de Lope, C Ayuso, J Bruix. Hepatology 2009;50:791-798
Pubmed abstract
A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. G Cabibbo, M Enea, M Attanasio, J Bruix, A Craxi, C Cammà. Hepatology 2010;51:1274-1283.
Pubmed abstract
MicroRNA-Based classification of hepatocellular carcinoma and oncogenic role of miR-517a. S Toffanin, Y Hoshida, A Lachenmayer, A Villanueva, L Cabellos, B Minguez, R Savic, SC Ward, S Thung, DY Chiang, C Alsinet, V Tovar, S Rayaie, M Schwartz, J Bruix, S Waxman, SL Friedman, T Golub, V Mazzaferro, JM Llovet. Gastroenterology 2011;140:1618-1628.
Pubmed abstract
Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. J Bruix, T Poymard, M Colombo, E Schiff, K Burak, EJ Healthcote, T Berq, JL Poo, CB Melllo, R Guenther, C Niederau, R Terg, P Bedossa, N Boparal LH Griffel, M Burroughs, CA Brass, JK Albrecht, Epic Study Group. Gastroenterology 2011;140:1990-1999.
Pubmed abstract
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. A Villanueva, Y Hoshida, C Battiston, V Tovar, D Sia, C Alsinet, H Cornella, A liberzon, M Kobayashi, H Kumada, SN Thung, J Bruix, P Newell, C April, JB Fan, S Roayaie, V Mazzaferro, ME Schwartz, JM Llovet. Gastroenterology 2011;140:1501-1512.
Pubmed abstract
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J; SHARP Investigators Study Group. Clin Cancer Res. 2012;Apr 15;:18(8):2290-300.
Pubmed abstract
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. J Hepatol. 2012;Oct;:57(4):821-9.
Pubmed abstract
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia-Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Gastroenterology. 2013;Apr;:144(4):829-40.
Pubmed abstract
Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Gastroenterology. 2013 ;May;:144(5):1024-30.
Pubmed abstract
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Nault JC, De Reyniès A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J. Gastroenterology. 2013;Jul;:145(1):176-87.
Pubmed abstract
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. J Clin Oncol. 2013;Oct 1;:31(28):3509-16.
Pubmed abstract
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Reig M, Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner A, Llarch N, Ríos J, Ayuso C, Bruix J. Hepatology. 2013;Dec; :58(6):2023-31.
Pubmed abstract
UHRF1 Overexpression Drives DNA Hypomethylation and Hepatocellular Carcinoma. Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, Senbanerjee S, Ukomadu C, Llovet JM, Sadler KC. Cancer Cell. 2014;Feb 10;:25(2):196-209.
Pubmed abstract